GnRH激动剂用于晚期前列腺癌临床试验设计指导原则 - 图文

五、参考文献

1. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;68:394-424.

2. 2015年中国恶性肿瘤流行情况分析.中华肿瘤杂志.2024;41:19-28. 3. 前列腺癌诊疗规范（2024年版）。国家卫生健康委员会。http://www.nhc.gov.cn/yzygj/s7659/202412/b21802b199814ab7b1219b87de0cae51.shtml

4. FDA. Advanced Prostate Cancer:Developing Gonadotropin Releasing Hormone

Analogues

Guidance

for

Industry.

https://www.fda.gov/media/129027/download

5. Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer. Eur J Clin Pharmacol. 2014;70:791-8. 6. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2017;18:825-832.

11